{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.3","upperLimit":"94.4","value":"83.3"},{"groupId":"OG001","lowerLimit":"62.5","upperLimit":"92.5","value":"80.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Response was evaluated using the international criteria proposed by the International Primary Central Nervous System Lymphoma (PCNSL) Study Group criteria. Complete Response was defined as no contrast brain enhancement on magnetic resonance imaging (MRI), no corticosteroid use for at least 2 weeks, a normal eye exam, and negative CSF cytology. Partial response was defined as at least 50% decrease in enhancing tumor on MRI compared with baseline imaging, no or minor retinal pigment epithelium (RPE) abnormality, and negative CSF cytology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG000","title":"Chemotherapy"},{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG001","title":"Chemotherapy + Low-Dose WBRT"}],"paramType":"NUMBER","populationDescription":"Eligible participants with Cycle 4 disease assessment data","reportingStatus":"POSTED","timeFrame":"After 4th cycle of chemotherapy, approximately 4 months after randomization.","title":"Percentage of Participants Experiencing Partial Response or Complete Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}